GenOway is intensifying its global expansion and anticipates robust growth

On November 3, 2026, genOway, a specialist in preclinical solutions, unveiled its ambition for significant growth in the first half of 2027, with an expected increase of over 20% in its Catalog Model sales. The company is accelerating its expansion in key markets such as the United States, Europe, and Asia.

In China, the joint venture, created in 2023, is achieving impressive performance, doubling its revenue to €2.4 million in the first half of 2026, with a target of €10 million in 2027. In parallel, the Japanese subsidiary is aiming for more than €1 million through active prospecting.

genOway is also strengthening its international presence with a new franchise in Spain and plans to have 10 franchises by the end of 2027. In the United States, the sales team is expanding with four new recruits, thus consolidating genOway's influence in this vital market.